Interestingly, there is a bias toward the right-sided CRC for the KRAS mutation, this may partially explain an inferior survival and poor response to targeted therapy with EGFR inhibitors for the right proximal CRC compared to the left colon CRC [56]. This evidence concerns the gene EGFR and colorectal carcinoma.